Loading
IB
Innovent Biologics, Inc. Stock: price and insider trades · Hong Kong
1 insider bought shares over the last 90 days, the latest by Ede Ronald Hao Xi, filed 07 Sept 2026.
Insider Decl.
100
Thresholds
n/a
Buy Volume
n/a
52 ops. · all time
Sell Volume
€504M
27 ops. · all time
Who traded when
BuySaleEde Ronald Hao Xi3 buys4 sales
Cooney Charles Leland2 buys1 sale
Yu De-Chao Michael2 buys1 sale
Zieziula Gary Joseph2 buys1 sale
Chen Shuyun2 buys
Hsu Joyce I-Yin2 buys
+2 other insiders
Since the insiders bought
- -8.6%Entry HK$89.30 · Close 22 Oct 2026 HK$81.60
- -8.6%Entry HK$89.30 · Close 22 Oct 2026 HK$81.60
- -8.6%Entry HK$89.30 · Close 22 Oct 2026 HK$81.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Innovent Biologics, Inc. Strong Buy (bullish), based on 29 analysts. Average price target: HK$129.89.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,919 of 26,280 companies
57.6
score / 100
Value52
Quality64
FCF yld6.0%
Earn yld0.5%
EV/EBITDA·
ROE7.0%
Gross mgn87%
Net mgn6.2%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$88.95
Analyst consensus
29 analystsStrong buy
HK$94.79Target HK$129.89(+46%)HK$156.89
Income statement
RevenueHK$13B
Gross profitHK$11.3B87% margin
EBITDAHK$1.5B12% margin
Net incomeHK$813.6M7.8% margin
Valuation
PER (trailing)117.0x
PER (forward)41.2x
P/Book6.4x
Beta0.33
Balance sheet & cash
Market capHK$155.1B
Total debtHK$2.8B
Free Cash FlowHK$9.3B
Debt / Equity11%
Profitability & ownership
ROE7.0%
ROA2.2%
% insiders6.2%
% institutions55.7%
Last declaration on 7 September 2026
Declarations100 total
7,043 sharesShareXHKGHKEX:DA20260904E00612
Canonical exit: 30 Nov 2026 (T+90)
38,628 sharesShareXHKGHKEX:DA20260901E00417
38,628 shares@ HK$107.99340.0023% mcap100.0% of flowShareXHKGHKEX:DA20260901E00418
752,381 sharesShareXHKGHKEX:DA20260708E00743
1,882,334 sharesShareXHKGHKEX:DA20260708E00741
752,381 shares@ HK$88.50420.038% mcap16.7% of flowShareXHKGHKEX:DA20260708E00744
1,882,334 shares@ HK$87.52750.094% mcap41.3% of flowShareXHKGHKEX:DA20260708E00742
43,431 shares@ HK$87.84160.0023% mcap100.0% of flowShareXHKGHKEX:DA20260519E00088
1,352,952 shares@ HK$89.3620.075% mcap100.0% of flowShareXHKGHKEX:DA20260512E00541
24,226 sharesShareXHKGHKEX:DA20260402E00009
Canonical exit: 28 Jun 2026 (T+90)
24,226 sharesShareXHKGHKEX:DA20260402E00005
Canonical exit: 28 Jun 2026 (T+90)
330,000 sharesShareXHKGHKEX:DA20260402E00008
Canonical exit: 28 Jun 2026 (T+90)
39,366 sharesShareXHKGHKEX:DA20260402E00007
Canonical exit: 28 Jun 2026 (T+90)
1,000,000 shares@ HK$85.00050.052% mcap21.2% of flowShareXHKGHKEX:DA20260402E00001
986,000 shares@ HK$85.000.051% mcap20.8% of flowShareXHKGHKEX:DA20260401E00593
24,226 sharesShareXHKGHKEX:DA20260402E00006
Canonical exit: 28 Jun 2026 (T+90)
24,226 sharesShareXHKGHKEX:DA20260402E00010
Canonical exit: 28 Jun 2026 (T+90)
1,863,000 sharesShareXHKGHKEX:DA20260402E00003
Canonical exit: 28 Jun 2026 (T+90)
225,000 sharesShareXHKGHKEX:DA20260402E00002
Canonical exit: 28 Jun 2026 (T+90)
6,900 sharesShareXHKGHKEX:DA20250902E00392
Canonical exit: 27 Nov 2025 (T+90)
82,790 sharesShareXHKGHKEX:DA20250402E00474
Canonical exit: 26 Jun 2025 (T+90)
19,106 sharesShareXHKGHKEX:DA20250402E00475
Canonical exit: 26 Jun 2025 (T+90)
19,106 sharesShareXHKGHKEX:DA20250402E00473
Canonical exit: 26 Jun 2025 (T+90)
1,023,500 sharesShareXHKGHKEX:DA20250402E00480
Canonical exit: 26 Jun 2025 (T+90)
19,106 sharesShareXHKGHKEX:DA20250402E00486
Canonical exit: 26 Jun 2025 (T+90)
25 of 100 declarations
About Innovent Biologics, Inc.
In Hong Kong, Innovent Biologics, Inc. shows 52 purchases with no known amount, against 27 sales, 22 of them with an amount, worth EUR 504.5 million in total (median EUR 7,768,699). Purchases represent 66% of open-market trades.
The largest sale, EUR 276,846,928, is Yu De-Chao Michael's, Director, on October 9, 2019, followed by EUR 49,325,401 on July 27, 2020; Ede Ronald Hao Xi, Director, sold EUR 40,161,696 on July 22, 2021. Yu De-Chao Michael has 32 filings, including 9 purchases and 13 sales; Ede Ronald Hao Xi has 22, including 9 purchases and 8 sales. Cooney Charles Leland (13 filings) and Hsu Joyce I-Yin (9) each filed mostly purchases, with 8. On March 30, 2026, 8 insiders reported transactions on the same day.
Read moreShow less
This healthcare company, valued at HKD 155.1 billion and 6.2% held by insiders, has published 100 filings from 9 filers, with a median delay of 5 days and 21 filings of other kinds. The first publication dates from November 13, 2018, the latest from September 7, 2026. 2024 and 2026 have 19 filings each, against 6 in 2018. Over twelve months: 19 filings, 9 purchases and 7 sales.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
